JP6937037B2 - Ｐｓｍａ標的化ｎｉｒ色素およびその使用 - Google Patents

Ｐｓｍａ標的化ｎｉｒ色素およびその使用 Download PDF

Info

Publication number
JP6937037B2
JP6937037B2 JP2018512411A JP2018512411A JP6937037B2 JP 6937037 B2 JP6937037 B2 JP 6937037B2 JP 2018512411 A JP2018512411 A JP 2018512411A JP 2018512411 A JP2018512411 A JP 2018512411A JP 6937037 B2 JP6937037 B2 JP 6937037B2
Authority
JP
Japan
Prior art keywords
psma
tumor
compound
cells
cancer cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018512411A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018535925A5 (https=
JP2018535925A (ja
Inventor
スミス エー． クララトネ，
スミス エー． クララトネ，
フィリップ エス． ロウ，
フィリップ エス． ロウ，
プラビン ガガレ，
プラビン ガガレ，
キャリー マイヤーズ，
キャリー マイヤーズ，
Original Assignee
オン ターゲット ラボラトリーズ エルエルシー
オン ターゲット ラボラトリーズ エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オン ターゲット ラボラトリーズ エルエルシー, オン ターゲット ラボラトリーズ エルエルシー filed Critical オン ターゲット ラボラトリーズ エルエルシー
Publication of JP2018535925A publication Critical patent/JP2018535925A/ja
Publication of JP2018535925A5 publication Critical patent/JP2018535925A5/ja
Application granted granted Critical
Publication of JP6937037B2 publication Critical patent/JP6937037B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052—Small organic molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C07K5/06095—Arg-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic
    • C07K5/06113—Asp- or Asn-amino acid
    • C07K5/06121—Asp- or Asn-amino acid the second amino acid being aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06147—Dipeptides with the first amino acid being heterocyclic and His-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06156—Dipeptides with the first amino acid being heterocyclic and Trp-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C07K5/0817—Tripeptides with the first amino acid being basic the first amino acid being Arg
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/17—Metallocarboxypeptidases (3.4.17)
    • C12Y304/17021—Glutamate carboxypeptidase II (3.4.17.21)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A61K49/0034—Indocyanine green, i.e. ICG, cardiogreen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
    • G01N2021/6439—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes" with indicators, stains, dyes, tags, labels, marks
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Optics & Photonics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Radiology & Medical Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2018512411A 2015-09-09 2016-09-08 Ｐｓｍａ標的化ｎｉｒ色素およびその使用 Active JP6937037B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562216157P 2015-09-09 2015-09-09
US62/216,157 2015-09-09
PCT/US2016/050709 WO2017044584A1 (en) 2015-09-09 2016-09-08 Psma-targeted nir dyes and their uses

Publications (3)

Publication Number Publication Date
JP2018535925A JP2018535925A (ja) 2018-12-06
JP2018535925A5 JP2018535925A5 (https=) 2019-07-25
JP6937037B2 true JP6937037B2 (ja) 2021-09-22

Family

ID=58189184

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018512411A Active JP6937037B2 (ja) 2015-09-09 2016-09-08 Ｐｓｍａ標的化ｎｉｒ色素およびその使用

Country Status (12)

Country Link
US (4) US9808538B2 (https=)
EP (1) EP3347019B1 (https=)
JP (1) JP6937037B2 (https=)
KR (1) KR102862158B1 (https=)
CN (2) CN121824666A (https=)
AU (1) AU2016318949B2 (https=)
BR (1) BR112018004726B1 (https=)
CA (1) CA2996309A1 (https=)
ES (1) ES2861528T3 (https=)
IL (1) IL257669B (https=)
MX (1) MX381760B (https=)
WO (1) WO2017044584A1 (https=)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4464384A3 (en) * 2007-08-17 2025-01-08 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
US20170232119A1 (en) * 2013-03-15 2017-08-17 Purdue Research Foundation Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors
LT4095130T (lt) 2013-10-18 2024-04-25 Novartis Ag Žymėti prostatos specifinio membranos antigeno (psma) inhibitoriai, jų naudojimas kaip vizualizavimo medžiagų ir farmacinių medžiagų prostatos vėžiui gydyti
BR112016010927A2 (pt) 2013-11-14 2017-08-08 Endocyte Inc Conjugado de fórmula
US9808538B2 (en) 2015-09-09 2017-11-07 On Target Laboratories, LLC PSMA-targeted NIR dyes and their uses
US10842887B2 (en) * 2015-09-09 2020-11-24 On Target Laboratories, LLC PSMA-targeted NIR dyes and their uses
US10913071B2 (en) 2016-03-09 2021-02-09 Pearson Incorporated Scalper apparatus and processing system
JP7285537B2 (ja) * 2016-03-16 2023-06-02 オン ターゲット ラボラトリーズ エルエルシー Ｃａ ｉｘ標的ｎｉｒ色素及びそれらの使用
US11555821B2 (en) 2016-03-16 2023-01-17 On Target Laboratories, Inc. CA IX-NIR dyes and their uses
US10322487B1 (en) 2016-07-15 2019-06-18 Pearson Incorporated Roller mill grinding apparatus with regenerative capability
EP3510399B1 (en) * 2016-09-09 2023-03-01 On Target Laboratories, LLC Psma-targeted nir dyes and their uses
CN107266929B (zh) * 2017-06-21 2019-10-29 四川大学 一类以菁染料荧光基团为母体骨架结构的近红外荧光染料及其制备方法与应用
US10807098B1 (en) 2017-07-26 2020-10-20 Pearson Incorporated Systems and methods for step grinding
CN108362671B (zh) * 2018-02-23 2020-11-13 银川高新区广煜科技有限公司 检测半胱氨酸的方法
WO2019173483A1 (en) * 2018-03-07 2019-09-12 The Board Of Trustees Of The Leland Stanford Junior University Drug fragment imaging agent conjugates
US12208102B2 (en) 2018-04-17 2025-01-28 Endocyte, Inc. Methods of treating cancer
US11325133B1 (en) 2018-07-26 2022-05-10 Pearson Incorporated Systems and methods for monitoring the roll diameter and shock loads in a milling apparatus
WO2020030954A1 (en) 2018-08-09 2020-02-13 Integrative Medicine Clinic, Sia Theranostics-like protein sanps conjugated to integrin and pmsa targeting peptides and therapy of prostate cancer
US10751722B1 (en) 2018-10-24 2020-08-25 Pearson Incorporated System for processing cannabis crop materials
US10785906B2 (en) 2019-02-19 2020-09-29 Pearson Incorporated Plant processing system
CN114096264B (zh) 2019-05-20 2025-03-14 因多塞特股份有限公司 制备psma缀合物的方法
RU2713151C1 (ru) * 2019-07-02 2020-02-04 Общество с ограниченной ответственностью "Изварино Фарма" Конъюгат флуоресцентного красителя с веществом пептидной природы, включающим псма-связывающий лиганд на основе производного мочевины для визуализации клеток, экспрессирующих псма, способ его получения и применения
US10757860B1 (en) 2019-10-31 2020-09-01 Hemp Processing Solutions, LLC Stripper apparatus crop harvesting system
US10933424B1 (en) 2019-12-11 2021-03-02 Pearson Incorporated Grinding roll improvements
CN113117099B (zh) * 2019-12-31 2022-07-15 广东精观生物医药科技有限公司 一种靶向psma的荧光分子探针及其制备方法和应用
US11964965B2 (en) * 2020-05-08 2024-04-23 On Target Laboratories, LLC Methods of manufacture and synthesis of fluorescent dye compounds and uses thereof
BR112023004869A2 (pt) * 2020-09-16 2023-04-18 On Target Laboratories Llc Detecção de células tumorais circulantes utilizando agentes nir direcionados a tumor
US20230417754A1 (en) * 2020-11-18 2023-12-28 On Target Laboratories, LLC Near infrared-ii probes as high affinity targeting imaging agents and uses thereof
WO2022167681A1 (en) * 2021-02-08 2022-08-11 Stichting Radboud Universitair Medisch Centrum Psma-targeting ligands for multimodal applications
CN115872950B (zh) * 2021-09-25 2024-04-16 上海交通大学医学院附属第九人民医院 荧光化合物及在检测尿素酶中的应用和体外诊断试剂
CN113979912B (zh) * 2021-11-16 2023-04-07 中国医学科学院肿瘤医院 两种前列腺特异性膜抗原靶向荧光探针及其制备方法与应用
CN114014843B (zh) * 2021-11-17 2022-09-20 北京大学第一医院 一种psma靶向核素/荧光双模态配体和分子探针与应用
CN114214061B (zh) * 2022-02-22 2022-05-17 北京大学 一种聚乙二醇修饰的两性离子化荧光探针、制剂及其应用
WO2023236778A1 (zh) * 2022-06-10 2023-12-14 北京大学 一种三功能化合物及其用途
CN114835723B (zh) * 2022-07-01 2022-09-16 戴格普瑞生物科技(苏州)有限公司 Psma荧光分子探针、制备方法及试剂盒
CN115490672B (zh) * 2022-09-30 2023-11-17 南华大学 一种兼具光热和光动力效应的光敏剂及其制备方法和应用
CN118978470B (zh) * 2023-05-10 2025-04-22 新斗生物科技(苏州)有限公司 化合物及其制备方法、组合物、试剂盒及应用
CN116621820B (zh) * 2023-05-23 2025-05-23 中山大学 一种两性离子荧光化合物及其制备方法和应用
KR20260009883A (ko) * 2023-05-24 2026-01-20 베이징 창핑 래보러토리 신규 삼관능 화합물 및 이의 용도
AU2024324648A1 (en) * 2023-08-14 2026-02-26 Cancer Targeted Technology Llc Psma binding ligand-linker conjugates and methods for use thereof
WO2025119908A1 (en) 2023-12-06 2025-06-12 Bracco Imaging Spa Psma-targeting fluorescent probes
US20250275943A1 (en) * 2024-01-30 2025-09-04 Korea University Research And Business Foundation Composition for cancer diagnosis targeting tumor and/or tumor microenvironment and use thereof
CN118048050B (zh) * 2024-04-16 2024-06-25 南京诺源医疗器械有限公司 一种七甲川菁近红外荧光染料及其制备方法和应用
CN118078219B (zh) * 2024-04-24 2024-08-02 新斗生物科技(苏州)有限公司 近红外荧光捕获系统、装置及应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19649971A1 (de) 1996-11-19 1998-05-28 Diagnostikforschung Inst Optische Diagnostika zur Diagnostik neurodegenerativer Krankheiten mittels Nahinfrarot-Strahlung (NIR-Strahlung)
US6326531B1 (en) 2000-08-01 2001-12-04 Neil Bremner Instrument case support system and method
US20100022449A1 (en) * 2006-03-09 2010-01-28 Mallinckrodt Inc. Receptor-avid exogenous optical contrast and therapeutic agents
JP2009532338A (ja) * 2006-03-14 2009-09-10 キャンサー ターゲテッド テクノロジー エルエルシー Ｐｓｍａのペプチド模倣体阻害剤、それらを含む化合物、およびそれらの使用方法
JP2010509570A (ja) * 2006-11-03 2010-03-25 パーデュー・リサーチ・ファウンデーション エクスビボフローサイトメトリーの方法および装置
EP4464384A3 (en) * 2007-08-17 2025-01-08 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
US9023611B2 (en) * 2009-02-06 2015-05-05 Beth Israel Deaconess Medical Center Charged-balanced imaging agents
EP3222617B1 (en) * 2009-03-19 2022-07-06 The Johns Hopkins University Psma-targeting compounds and uses thereof
CA2790577A1 (en) * 2010-02-25 2011-09-01 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
EP2958596B1 (en) * 2013-02-15 2019-12-04 Case Western Reserve University Psma ligands and uses thereof
WO2014149069A1 (en) 2013-03-15 2014-09-25 Purdue Research Foundation Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors
US10406246B2 (en) * 2013-10-17 2019-09-10 Deutsches Kresbsforschungszentrum Double-labeled probe for molecular imaging and use thereof
US9808538B2 (en) 2015-09-09 2017-11-07 On Target Laboratories, LLC PSMA-targeted NIR dyes and their uses

Also Published As

Publication number Publication date
BR112018004726B1 (pt) 2023-10-03
US9968691B2 (en) 2018-05-15
WO2017044584A1 (en) 2017-03-16
ES2861528T3 (es) 2021-10-06
US9801956B2 (en) 2017-10-31
US20170281801A1 (en) 2017-10-05
EP3347019A4 (en) 2019-05-01
KR20180071258A (ko) 2018-06-27
US9808538B2 (en) 2017-11-07
IL257669A (en) 2018-04-30
US20170066719A1 (en) 2017-03-09
CA2996309A1 (en) 2017-03-16
BR112018004726A2 (en) 2018-09-25
US10456482B2 (en) 2019-10-29
US20170065729A1 (en) 2017-03-09
US20170319717A1 (en) 2017-11-09
CN108135903A (zh) 2018-06-08
MX381760B (es) 2025-03-13
EP3347019A1 (en) 2018-07-18
KR102862158B1 (ko) 2025-09-18
IL257669B (en) 2022-02-01
AU2016318949B2 (en) 2022-05-19
CN121824666A (zh) 2026-04-10
MX2018002933A (es) 2018-09-18
AU2016318949A1 (en) 2018-04-05
JP2018535925A (ja) 2018-12-06
EP3347019B1 (en) 2021-01-13

Similar Documents

Publication Publication Date Title
JP6937037B2 (ja) Ｐｓｍａ標的化ｎｉｒ色素およびその使用
US10308606B2 (en) PSMA-targeted NIR dyes and their uses
US20240350677A1 (en) Psma-targeted nir dyes and their uses
US10881747B2 (en) Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors
JP6793122B2 (ja) 術中イメージング
CA2961095C (en) Upar targeting peptide for use in perioperative optical imaging of invasive cancer
Laydner et al. Robotic real-time near infrared targeted fluorescence imaging in a murine model of prostate cancer: a feasibility study

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190619

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190619

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200611

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200623

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200918

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201223

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210427

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210730

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210823

R150 Certificate of patent or registration of utility model

Ref document number: 6937037

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250